Human Ig superfamily CTLA‐4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA‐4 cytoplasmic domains

Dariavach, Piona; Matteï, Marie‐Geneviève; Golstein, Pierre; Lefranc, Marie‐Paule

doi:10.1002/eji.1830181206

Cited by 268 publications

(163 citation statements)

References 28 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Detectable levels of sCTLA-4 have been demonstrated in human serum by immunometric assays and western blot analysis [10,11,13,20,49,51,53,[55][56][57][58][59][60]. Recently, however, on the basis of mass spectrometry and biochemical evaluation, the possibility that at least some of the B7 binding material isolated from serum by means of CTLA4 antibodies is not a product of the CTLA4 gene has been considered [61].…”

Section: Soluble Form Of Ctla-4mentioning

confidence: 99%

The soluble CTLA-4 receptor and its role in autoimmune diseases: an update

Saverino

Simone

Bagnasco

et al. 2010

Autoimmun Highlights

View full text Add to dashboard Cite

CTLA-4, initially described as a membranebound molecule, is a costimulatory receptor transducing a potent inhibitory signal. Increasing evidence shows the CTLA-4 gene to be an important susceptibility locus for autoimmune endocrinopathies and other autoimmune disorders. A soluble form of cytotoxic T-lymphocyte-associated antigen-4 (sCTLA-4) has been established and shown to possess CD80/CD86 binding activity and in vitro immunoregulatory functions. sCTLA-4 is generated by alternatively spliced mRNA. Whereas low levels of sCTLA-4 are detected in normal human serum, increased serum levels are observed in several autoimmune diseases (e.g. Graves’ disease, myasthenia gravis, systemic lupus erythematosus, type 1 diabetes, systemic sclerosis, coeliac disease, autoimmune pancreatitis and primary biliary cirrhosis). The biological significance of increased sCTLA-4 serum levels is not fully clarified yet. On the one hand, it can be envisaged that sCTLA-4 specifically inhibits early T-cell activation by blocking the interaction of CD80/CD86 with the costimulatory receptor CD28. On the other hand, higher levels of sCTLA-4 could compete for the binding of the membrane form of CTLA-4 with CD80/CD86 in the later phases of T-lymphocyte activation, causing a reduction in inhibitory signalling. This double-edged nature of sCTLA-4 to block the binding of CD28 to CD80/CD86 may result in different outcomes during the clinical course of an autoimmune disease.

show abstract

Section: Soluble Form Of Ctla-4mentioning

confidence: 99%

The soluble CTLA-4 receptor and its role in autoimmune diseases: an update

Saverino

Simone

Bagnasco

et al. 2010

Autoimmun Highlights

View full text Add to dashboard Cite

show abstract

“…The human CTLA-4 gene was cloned in 1988 [33,48]. Pfizer's preclinical immunology team focused on CTLA-4 as a potential target before it was clear whether it was a positive or negative costimulatory receptor [49].…”

Section: Goals For the Development Of Ctla-4 -Blocking Absmentioning

confidence: 99%

Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

Ribas

Hanson

Noe³

et al. 2007

The Oncologist

150

115

View full text Add to dashboard Cite

After completing the course, the reader will be able to:1. Educate community oncologists about the promise of anti-CTLA-4 monoclonal antibodies for the treatment of advanced cancer. 2. Suggest that CTLA-4 blockade overcomes barriers to effective immunotherapy for cancer. 3. Describe the rational design and clinical development strategy taken with the CTLA-4 antagonist tremelimumab.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

show abstract

“…The CTLA-4 gene consists of 4 exons and has been mapped to chromosome 2q33.3 (Dariavach et al, 1988). The four most frequently studied polymorphisms are a dinucleotide repeat in the 3V untranslated region, an A/G transition in exon 1 at position +49, a C/T transition in the À318 position of the promoter sequence and more recently a C/T transition within the 3V-untranslated region (Ueda et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

The CTLA4 + 49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland

Suppiah

O’Doherty

Heggarty

et al. 2006

Experimental and Molecular Pathology

View full text Add to dashboard Cite

Rheumatoid and juvenile idiopathic arthritis (RA, JIA) are chronic inflammatory arthropathies with an autoimmune background. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) protein plays a key role in the down-regulation of T cell activation.We analyzed the CTLA4 +49A/G and CT60 polymorphisms in cohorts of Northern Irish RA and JIA patients and healthy control subjects using restriction fragment length polymorphism methods.The +49 A allele was increased in RA (61.2%; P = 0.02; OR = 1.28; 95% C.I. = 1.04 -1.58) and JIA (61.8%; P = 0.14) patients compared to the control population (55.3%). No significant association was observed for the CT60 polymorphism. Haplotype analysis revealed a significantly different distribution of +49 A/G-CT60 haplotypes in RA and JIA patients compared to controls ( P value < 0.00001 and 0.030 for comparison of RA and JIA patients with controls, respectively).Our results suggest that the CTLA-4 gene is involved in predisposition to inflammatory arthropathies in the Northern Irish population. D

show abstract

Human Ig superfamily CTLA‐4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA‐4 cytoplasmic domains

Cited by 268 publications

References 28 publications

The soluble CTLA-4 receptor and its role in autoimmune diseases: an update

The soluble CTLA-4 receptor and its role in autoimmune diseases: an update

Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

The CTLA4 + 49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland

Contact Info

Product

Resources

About